On Apr. 7, 2020, Pluristem Therapeutics announced preliminary data from its compassionate use program, treating seven patients suffering from acute respiratory failure and inflammatory complications associated with COVID-19 with Pluristemﾒs PLX cells, in three medical centers in Israel. Six of the seven patients have completed the seven day follow up period (ﾓGroup Aﾔ). The seventh patient has not yet completed seven day follow up.